Last updated: 2026-09-16 09:45:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Acumen Pharmaceuticals, Inc. (ABOS) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $2,90, with a market capitalisation of $201,77M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,21 to $3,60. This page covers its latest market performance, valuation, price trends and company information.
$201,77M | |
$2,77 | |
$26,98 | |
$0,86 | |
$2,79 | |
321,03K | |
473,52K | |
-- | |
$3,60 | |
$1,21 | |
-- | |
-- |
Acumen Pharmaceuticals, Inc. (ABOS) is trading at $2,82 in pre-market trading as of 2026-09-15 23:31:00, up 1,04% ($0,03) from the previous close of $2,79
Pre-market trading shows how investors are pricing ABOS before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Acumen Pharmaceuticals, Inc. (ABOS) moved from $3,18 to $2,90, representing a decline of 8,96% ($0,29).
The stock traded between $2,69 and $3,29 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 369,10 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 70,5%
ABOS is currently trading at $2,90, placing it 70,5% of the way from its 52-week low of $1,21 to its 52-week high of $3,60. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 61 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Acumen Pharmaceuticals, Inc. (ABOS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.